Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues
Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported...
HKG: 2186
Luye Pharma’s Subsidiary Boan Bio Reports 2024H1 Revenue Growth and First Full Year of Profitability
Luye Pharma Group, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2186), has announced...
Luye Pharma’s LY03020 Receives NMPA Approval for Schizophrenia and Alzheimer’s Psychosis Treatment
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that it has received...
Luye Pharma’s Antipsychotic Erzofri Gains FDA Nod for Schizophrenia Treatment
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has achieved a...
Luye Pharma’s Subsidiary Gets NMPA Go-Ahead for First CD228-Targeted ADC BA1302
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a subsidiary of China-based Luye Pharma Group (HKG:...
Luye Pharma Group Secures RMB 1.6 Billion Investment to Boost Financials and R&D
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Luye Pharma’s Oxycodone/Naloxone Product Receives NMPA Approval for Severe Pain Management
Luye Pharma Group (HKG: 2186), a pharmaceutical company based in China, has announced that it...
Luye Pharma’s Manufacturing Facility Passes FDA Inspection for Paliperidone Palmitate Product
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that it has successfully...
Luye Pharma’s Once-Weekly Parkinson’s Disease Treatment Receives NMPA Approval
Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from the...
Luye Pharma’s Paliperidone Palmitate Injection Wins NMPA Nod for Schizophrenia Treatment
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Luye Pharma Submits Market Approval Application for Rivastigmine Patch in Japan
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...
Luye Pharma’s Subsidiary Gets NMPA Green Light for Biosimilar Xgeva
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a controlling subsidiary of China-based Luye Pharma Group...
Luye Pharma’s Subsidiary Boan Biotech Completes Phase III Trial for Eylea Biosimilar BA9101
Shandong Boan Biotechnology Co., Ltd., a subsidiary of China-based Luye Pharma Group (HKG: 2186), has...
Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its...
Luye Pharma Launches Small-Cell Lung Cancer Treatment Zepzelca in Hong Kong and Macau
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the official market launch...
Luye Pharma Initiates Phase III Clinical Trial for Irinotecan Liposome Injection in Small-Cell Lung Cancer
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the enrollment of the...
Luye Pharma Grants Myung In Pharm Rights to Rivastigmine Patch for Alzheimer’s Treatment in South Korea
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced a licensing agreement with...
Luye Pharma’s Paliperidone Palmitate NDA Avoids Patent Lawsuit, Clears Path for FDA Approval
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that the New Drug...
Luye Pharma’s Biosimilar Bevacizumab Gets GMP Certification in Brazil
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Luye Pharma’s Lurbinectedin Receives Market Approval in Hong Kong for SCLC Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that Hong Kong’s pharmacy and poisons board...